Cobimetinib (C) + paclitaxel (P) as first-line treatment in patients (pts) with advanced triple-negative breast cancer (TNBC): Updated results and biomarker data from the phase 2 COLET study.
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Adam Brufsky, Sung-Bae Kim, Thierry J. Velu, Jose Angel Garcia Saenz, Elizabeth Tan-Chiu, Joohyuk Sohn, Luc Yves Dirix, Jaroslav Vanasek, Marleen V. Borms, J. Ignacio Delgado Mingorance, Mei-Ching Liu, Mehdi M. Moezi, Mark Kozloff, Joseph A. Sparano, Jessie J. Hsu, Matthew Wongchenko, Brian P. Simmons, V. A. McNally, David Miles
Institutions: Magee-Womens Hospital, NRG Oncology, Asan Medical Center, University of Ulsan, Centre Hospitalier Interrégional Edith Cavell, Hospital Clínico San Carlos, Florida Cancer Care, Severance Hospital, Yonsei University Health System, AZ Groeninge, Government of Extremadura, Koo Foundation Sun Yat-Sen Cancer Center, Ingalls Memorial Hospital, Albert Einstein College of Medicine, Montefiore Medical Center, Genentech, Roche (United Kingdom), Mount Vernon Cancer Centre
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2733487397